Dostinex, containing cabergoline, directly impacts prolactin levels. It acts as a dopamine agonist, mimicking the effects of dopamine in the brain.
This dopamine stimulation suppresses prolactin release from the pituitary gland. Reduced prolactin then addresses underlying conditions linked to elevated prolactin, such as hyperprolactinemia.
The drug binds to dopamine D2 receptors, triggering a cascade of intracellular events leading to decreased prolactin synthesis and secretion. This mechanism is relatively specific, targeting prolactin production without significantly impacting other hormones.
Cabergoline’s long half-life means fewer doses are needed compared to other medications, contributing to better patient compliance. However, individual responses vary, and dosage adjustments may be necessary.
Consult your doctor to determine if Dostinex is the right treatment option and to discuss potential side effects and interactions with other medications. They can tailor a treatment plan based on your specific needs and medical history.
